The Acute Myeloid Leukemia Channel is supported through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
STAT3 inhibition in MDS and AML
Aditi Shastri, MD, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY, presents on STAT3 inhibition in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Dr Shastri discusses the role of STAT3 in MDS/AML, a STAT3 degrader that has shown activity in therapy-resistant leukemic cell lines, and the agent danvatirsen, which will be tested clinically in relapsed/refractory MDS/AML. This presentation took place at the 8th International Workshop on Acute Leukemias (iwAL) in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
